Objective β-adrenergic antagonists (β-blockers) are often used to attenuate the hyperadrenergic symptoms of Graves' disease (GD), including palpitation. Although β-blockers reduce the heart rate, cardiac output and oxygen consumption, no firm evidence exists regarding the effects of combined therapy with β-blockers and anti-thyroid drugs. The objective is to elucidate the effects of β-blockers on anti-thyroid drug therapy in GD. Methods Patients newly diagnosed with mild GD were randomly assigned to receive methimazole with or without β-blockers in a prospective multi-center survey. The heart rate and thyroid function were measured and the quality of life was assessed using original and SF-36 questionnaires at 0 and 4 weeks. Results A total of 28 patients were enrolled in the study. Fourteen patients (one man, 13 women) were randomly assigned to the group treated with β-blockers and 14 patients (one man, 13 women) were randomly assigned to the group not treated with β-blockers. Although no significant differences in the improvement of thyroid function were observed between the two groups, the heart rates improved more significantly in the group treated with β-blockers. Specific symptoms, such as easy fatigability and shortness of breath, also improved more significantly with the β-blocker treatment. In addition, 'physical functioning' assessed with the SF-36 questionnaires significantly improved only in the group treated with β-blockers. Conclusion Although β-blockers may not reinforce the effects of anti-thyroid drugs on thyroid function, at least during the course of one month, they are effective in reducing heart rates and ameliorating specific symptoms in patients with mild GD.
Introduction
Thyrotoxicosis is a clinical syndrome caused by an excess of thyroid hormones. Many of the clinical features of thyrotoxicosis, such as palpitations, tremors, nervousness, sweating and heat intolerance, mimic the manifestations of excess β-adrenergic activity (1, 2) . β-adrenergic blocking agents (β-blockers) have been used to treat thyrotoxicosis for the past 40 years, as these agents rapidly ameliorate many of the signs and symptoms observed in patients with thyrotoxicosis (3) .
The principal mechanism of action of β-blockers in thyrotoxicosis is to antagonize the β-receptor-mediated effects of catecholamines. β-blockers provide significant symptomatic relief when used alone in transient thyrotoxicosis conditions such as destructive thyroiditis (4) . They are also used in preparation for surgical management or as adjuncts to radioiodine in patients with Graves' disease (GD), the main cause of thyrotoxicosis (1, 5) . Although it has been established that β-blockers are effective for treating severe hyperthyroidism and thyroid storm (6) , the efficacy of β-blockers as adjuncts to anti-thyroid drugs has not been proven (7) .
In the present study, we examined the effects of β-blockers on anti-thyroid drug therapy in patients with mild GD. Newly diagnosed GD patients were randomly assigned to two groups treated with methimazole with or without β-blockers. Thyroid function tests and quality of life assessments were completed in a prospective multi-center survey. This is the first report to study the effects of β-blockers on the thyroid function and quality of life of patients with GD treated with anti-thyroid drugs to prevent thyrotoxicosis.
Materials and Methods

Patients
Only patients newly diagnosed with mild GD between 2006 and 2010 were recruited. A diagnosis of GD was made based on the Japan Thyroid Association's guidelines for the diagnosis of GD (http://www.japanthyroid.jp/), which define GD according to clinical and laboratory findings such as elevated levels of free thyroxine (FT4) and/or free triiodothyronine (FT3), suppressed levels of thyrotropin (TSH), positive results for TSH-binding inhibitor immunoglobulins (TBII) or thyroid-stimulating antibodies (TSAb) and elevated radioactive iodine (or 99m Tc pertechnetate) uptake to the thyroid gland. Mild GD was defined as less than 6 ng/ dL of FT4 (8) and a heart rate of 90-130/min in order to exclude severe GD, which is a strong indicator of β-blockers. The level of FT3 was not evaluated in the definition of mild GD because FT3 levels may vary with nonthyroidal illness. Heart rates were assessed using ECG after 10 minutes of bed rest, and a heart rate of 90-130/min was considered to be compatible with a pulse rate of 100-140/min in the consultation room (unpublished observation), which was initially designated as moderate sinus tachycardia (9) . Patients with the following conditions were excluded from the study: age less than 18 or greater than 65 years, pregnancy or complications contraindicating the use of β-blockers, such as asthma, chronic obstructive lung disease, sick sinus syndrome, congestive heart failure or insulin-requiring diabetes.
The study was conducted in accordance with the Ethical Guidelines of the Japanese Ministry of Health and Labor for clinical studies. The study was approved by the ethical committee of the National Hospital Organization of Kyoto Medical Center and the ethical committee of our individual institution. Because this study was designed in 2005 when the preregistration system had not been established, the clinical trial registry was not used. After physicians obtained written informed consent from all patients, the participants were randomized into one of two groups described below using a closed envelop system. Enrollment and data collection were completed in the analysis center, which was completely independent of all of the participating institutions.
Group A: Patients treated with methimazole alone. Group B: Patients treated with methimazole and a β-blocker without intrinsic sympathomimetic activity, such as propranolol, metoprolol or atenolol. The adopted β-blocker varied among institutions. The dose of methimazole was set as 15 mg daily for patients with mild GD according to the therapeutic guidelines of the Japan Thyroid Association (10, 11) .
Assessment of physical and psychological conditions
Goiter size was calculated as the transverse diameter and manually measured by a physician. Resting heart rates were evaluated with electrocardiogram after 10 minutes of bed rest. Quality of life assessments were completed with the Japanese SF-36 version 2 and original questionnaires. The SF-36 is a short form health survey that assesses the physical and psychological health status of the patient (12, 13) . The original questionnaires included the assessment of neck swelling, palpitations, hyperhidrosis, body itching, thirst, heat intolerance, tremors, muscle weakness, easy fatigability, general malaise, body weight loss, low grade fever, edema of the lower extremities, shortness of breath, irritability, apathy, lack of concentration, insomnia, hyperorexia, hypoorexia, loose stools, ophthalmopathy and menstrual disorders in premenopausal women. The assessments were expressed with five ranks (none to severe) of subjective symptoms. All assessments were completed at 0 and 4 weeks.
Laboratory evaluation
Various laboratory parameters, such as the levels of aspartate aminotransferase, alanine aminotransferase and white blood cells were assessed using standard laboratory methods to monitor the adverse effects of methimazole. The serum concentrations of TSH (normal: 0.27-4.20 mU/L), FT4 (normal: 1.0-1.8 ng/dL) and FT3 (normal: 2.3-4.0 pg/mL) were determined using electro-chemiluminescence immunoassay (ECLIA, Roche Diagnostics, Tokyo, Japan). TBII was assayed using a commercial radio receptor assay (RRA) (DYNOtest TRAK human, Brahms AG, Berlin, Germany or TRAb, Cosmic Corp., Cardiff, UK) and TSAb was assayed using a commercial bioassay (TSAb, Brahms AG, Berlin, Germany). 
Statistical analysis
The Mann-Whitney U test was performed to investigate the differences between two groups and the Wilcoxon signed-rank test was applied to evaluate improvements after four weeks of treatment. All analyses were performed using a statistical software, PASW Statistics 18 (SPSS Japan Inc., Tokyo, Japan).
Results
A total of 28 patients were enrolled in the study without gender selection. Fourteen patients (one man, 13 women) were randomly assigned into group A (without β-blockers) and 14 patients (one man, 13 women) were randomly assigned into group B (with β-blockers). The baseline profiles are summarized in Table 1 . The mean ages of groups A and B were 38.7±13.1 and 44.1±13.8 years, respectively. The mean goiter sizes in groups A and B were 5.7±0.9 and 6.1± 1.2 cm, respectively. No significant differences in age, goiter size or any other initial parameter were observed between the two groups.
After four weeks of treatment with 15 mg of methimazole with or without β-blockers, resting heart rates, thyroid function and psychological conditions were re-evaluated (Table 2). Heart rates and the levels of FT4 and FT3 decreased significantly in both groups. The heart rates measured at four weeks in group B were significantly low compared with those measured in group A. In contrast, no significant differences in the levels of FT4 or FT3 measured at four weeks were observed between the two groups. Next, we compared changes in symptoms using an originally designed questionnaire, as described in Table 2 . The severity of the symptoms was ranked as 1 (none), 2 (very little), 3 (little), 4 (moderate) or 5 (severe) by the patients. The severity of palpitations, hyperhidrosis, thirst, tremors and muscle weakness improved significantly in both groups, whereas the severity of neck swelling, easy fatigability, general malaise, body weight loss, shortness of breath, irritability, apathy and lack of concentration improved in group B only. In contrast, the severity of body itching improved in group A only. The scores of easy fatigability and shortness of breath obtained at four weeks were significantly low in group B compared with those observed in group A. We also compared the changes in quality of life assessments using SF-36 questionnaires (Table 2) . Although no statistical differences were observed in initial and final scores in any parameter of the SF-36 assessment, 'physical functioning' significantly improved in group B only. Finally, no significant changes in laboratory parameters such as the levels of aspartate aminotransferase, alanine aminotransferase and white blood cells were observed in any of the patients during the four weeks of treatment. No adverse reactions induced by β-blockers were observed in group B. Because seven patients were treated with propranolol and seven patients were treated with either atenolol or metoprolol coincidentally (Table 1) , we also compared the values of several parameters between these two groups. No differences in the improvement of thyroid function or heart rate were observed. Although no differences were observed in improvements of quality of life assessments using SF-36, scores of 'shortness of breath' increased more significantly (p=0.01) in the group treated with atenolol or metoprolol (3.9 to 1.7 pts) than in the group treated with propranolol (3.7 to 2.7 pts).
Discussion
Although the use of β-blockers in the management of thyrotoxicosis is well established (1, 14, 15) , the mechanisms whereby β-blockers ameliorate the signs and symptoms of thyrotoxicosis remain unclear. Propranolol has no effect on radioiodine uptake, thyroid iodine release, T4 turnover or thyroid protein synthesis (16) (17) (18) . Although β-blockers might work by directly inhibiting the sympathetic activity, the sympathetic nervous system and the adrenal medulla are not overactive in thyrotoxicosis, and the circulating concentration and urinary excretion of catecholamines are normal or even low in patients with thyrotoxicosis (2) . Whether a change in the number of β-receptors occurs is also controversial and β-blockers do not appear to alter catecholamine sensitivity (2) . The major effect of propranolol appears to be inhibition of microsomal 5'-monodeiodinase, the enzyme responsible for deiodination of T4 to T3 and rT3 to 3,3'-T2 (19) (20) (21) . However, because only high doses (above 160 mg/day) of propranolol can slowly decrease serum T3 concentrations by as much as 30% (22), no differences in the FT3 values were observed after four weeks of treatment with mild to moderate doses of β-blockers in the current study.
In contrast, the heart rates measured at four weeks were expectedly significantly low in the group treated with β-blockers. Although β-blockers predominantly affect heart rates, it is reported that β-blockers also improve nervousness, sweating, tremors and muscle weakness (1) (2) (3) . In this study, specific symptoms such as 'easy fatigability' and 'shortness of breath' improved more significantly with β-blocker treatment, and 'physical functioning' assessed using SF-36 improved in the group treated with β-blockers only. This may be explained by the observation that a 10% reduction in oxygen consumption and basal metabolic rate is obtained with long-term oral use of selective or nonselective β-blockers (23, 24) . The reason why no apparent differences in the severity of 'palpitations' were observed, despite the observed differences in heart rates, is unclear. Alternatively, even if no patients complain of 'palpitations,' the use of β-blockers may be beneficial for improving the physical function of patients.
Although the present study was performed prospectively, there are some possible limitations. First, the sample size may have been too small to detect subtle differences in the improvement of quality of life assessments. The main difficulty in recruiting patients was the strict indication of enrollment included mild GD with moderate tachycardia, as described in the Patients section. Therefore, it took a relatively long time to complete the study. Second, the types of β-blockers used were not standardized because this study was completed as a multi-center study. β-blockers without intrinsic sympathomimetic activity were selected to achieve the primary aim of ameliorating tachycardia in thyrotoxicosis. Consequently, propranolol, metoprolol and atenolol were used. Comparative studies suggest that atenolol (200 mg daily) and metoprolol (200 mg daily) produce beneficial clinical responses equal to those seen with propranolol (160 mg daily) (1), which is the drug most frequently used. Finally, we compared the effects between groups treated with and without β-blockers instead of placebo. Initially, we considered using anti-anxiety agents as placebos but chose not to do this because the use of anti-anxiety agents may also make it difficult to judge the results. Therefore, it cannot be denied that some placebo effects played a role in the symptomatic relief achieved in the patients treated with β-blockers.
In this study, we examined the effects of β-blockers on anti-thyroid drug therapy in patients with mild GD. Although no improvements in thyroid function were observed, a combination of β-blockers and anti-thyroid drugs was shown to improve specific symptoms including easy fatigability and shortness of breath, and the heart rate. Therefore, we suggest that a combination of β-blockers and methimazole helps to improve symptoms in patients with mild GD. Further study using a placebo in a larger scale, however, needs to be carried out in the future.
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